ArticleJCI insight2017
Reversible retinal vessel closure from VEGF-induced leukocyte plugging.
Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 55 citations in OpenAlex.
- SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.American journal of ophthalmology · 2021Trial
- Retinal microstructural disorganization in persistent macular edema secondary to branch retinal vein occlusion: an adaptive optics OCT study.Scientific reports · 2026Observational
- Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide - a review.International journal of retina and vitreous · 2026Review
- Fibulin-7 and its bioactive fragments: emerging immunomodulatory roles in disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Causal Associations of Smoking, Alcohol, Obesity, Sedentary Behavior, Hypertension, and Hyperglycemia With Retinal Vein Occlusion: A Mendelian Randomization Study.Current genomics · 2025Article
- Exploration Progress on Inflammatory Responses and Immune Regulatory Mechanisms in Diabetic Retinopathy.Journal of inflammation research · 2025Review
- The Effects of Anti-Vascular Endothelial Growth Factor Loading Injections on Retinal Microvasculature in Diabetic Macular Edema.Translational vision science & technology · 2024Article
- Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy.American journal of ophthalmology case reports · 2024Article
- Perspectives of diabetic retinopathy-challenges and opportunities.Eye (London, England) · 2023Review
- Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway.Diabetes · 2023Article
- Vascular cell-adhesion molecule 1 (VCAM-1) regulates JunB-mediated IL-8/CXCL1 expression and pathological neovascularization.Communications biology · 2023Article
- Article
- The Changes of Irisin and Inflammatory Cytokines in the Age-Related Macular Degeneration and Retinal Vein Occlusion.Frontiers in endocrinology · 2022Article
- Analysis of the Cytokine Expression in the Aqueous Humor of Individuals with BRVO-Associated Macular Edema.Journal of ophthalmology · 2022Article
- AS1411 Nucleolin-Specific Binding Aptamers Reduce Pathological Angiogenesis through Inhibition of Nucleolin Phosphorylation.International journal of molecular sciences · 2021Article
- Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture.Investigative ophthalmology & visual science · 2021Article
- Anatomic-Functional Correlates in Lesions of Retinal Vein Occlusion.Investigative ophthalmology & visual science · 2021Observational
- Microvascular Structure Changes After Intravitreal Ranibizumab Injection in Retinal Vein Occlusion Patients With and Without Macular Ischemia.Frontiers in medicine · 2021Article
- Retinal vascular occlusions.Lancet (London, England) · 2020Review
- Efficacy of intravitreal AFlibercept injection For Improvement of retinal Nonperfusion In diabeTic retinopathY (AFFINITY study).BMJ open diabetes research & care · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Clinical trials in patients with macular edema due to diabetic retinopathy or retinal vein occlusion (RVO) have shown that suppression of VEGF not only improves macular edema, but also reopens closed retinal vessels, prevents progression of vessel closure, and improves retinopathy. In this study, we show the molecular basis for those clinical observations. Increased retinal levels of VEGF in mice cause plugging of retinal vessels with leukocytes, vessel closure, and hypoxia. Suppression of VEGF reduces leukocyte plugging, causing reperfusion of closed vessels. Activation of VEGFR1 contributes to leukocyte recruitment, because it is significantly reduced by an anti-VEGFR1-neutralizing antibody. High VEGF increases transcriptional activity of NF-κB and expression of NF-κB target genes, particularly Vcam1. Injection of an anti-VCAM-1-neutralizing antibody reduces VEGF-induced leukocyte plugging. These data explain the broad range of benefits obtained by VEGF suppression in patients with ischemic retinopathies, provide an important insight into the pathogenesis of RVO and diabetic retinopathy, and suggest that sustained suppression of VEGF early in the course of these diseases may prevent vessel closure, worsening ischemia, and disease progression. This study also identifies VEGFR1 and VCAM-1 as molecular targets whose suppression could supplement VEGF neutralization for treatment of RVO and diabetic retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.